Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). FDA label
Also known as Mozobil
plerixafor GZ316455 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| granulocyte colony-stimulating factor alone | ACTIVE_COMPARATOR | G-CSF administered up to 8 days |
| granulocyte colony-stimulating factor plus plerixafor | EXPERIMENTAL | G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7) |
| Granulocyte colony-stimulating factor (G-CSF) alone | ACTIVE_COMPARATOR | G-CSF administered up to 8 days |
| G-CSF plus plerixafor | EXPERIMENTAL | G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7) |
| Name | Type | Description |
|---|---|---|
| plerixafor GZ316455 | DRUG | Pharmaceutical form:vial Route of administration: subcutaneous injection |
| Filgrastim | DRUG | Pharmaceutical form:vial Route of administration: subcutaneous injection |
Inclusion criteria: * Age 20 to 75. * Japanese participants with histological or pathological diagnosis of NHL. * First or second complete response (CR) or partial response (PR). Exclusion criteria: * Leukemia participants. * Myelodysplastic syndrome (MDS) participants. * Less than 2 weeks since ...
Top 20 of 70 competitors
Plerixafor GZ316455 is used to mobilize and collect peripheral hematopoietic stem cells in patients with lymphoma and multiple myeloma. It is given with granulocyte colony-stimulating factor before stem cell collection. Sanofi is developing it, and it is in Phase 2 clinical development.
Plerixafor GZ316455 targets CXCR4, a chemokine receptor. It acts as a partial agonist at this receptor. By binding CXCR4, it helps release hematopoietic stem cells from the bone marrow into the bloodstream for collection.
Plerixafor GZ316455 is developed by Sanofi, which trades under the ticker SNY. Sanofi is the company responsible for its clinical development in lymphoma and multiple myeloma.
Plerixafor GZ316455 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 trials have been completed, and no active trials are currently listed.
Plerixafor GZ316455 has been studied in two completed Phase 2 trials. NCT02221492 evaluated it with G-CSF in Japanese participants with non-Hodgkin lymphoma, enrolling 32 patients. NCT02221479 evaluated it with G-CSF in Japanese participants with multiple myeloma, enrolling 14 patients.